Cytokinetics Inc
CYTK
Market Cap$3.87B
Close$
$-12.25
137% downside
Current Fair Value
137% downsideOvervalued by 137% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.87 Billion |
|---|---|
| Enterprise Value | $4.64 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.26 |
| Beta | 0.59 |
| Outstanding Shares | 118,496,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.25 |
|---|---|
| PEG | -32.92 |
| Price to Sales | - |
| Price to Book Ratio | -11.04 |
| Enterprise Value to Revenue | 241.58 |
| Enterprise Value to EBIT | -8.69 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | -3.17 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cytokinetics Inc
CEO: Robert Blum